QUEEN MARY UNIVERSITY OF LONDON

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Private

Established: 1882-01-08

Employees: 1K

Market Cap: -

Website: http://www.qmul.ac.uk

Clinical Trials

PAKT: AZD5363 in Combination With Paclitaxel in Triple-Negative Advanced or Metastatic Breast Cancer

Phase 2

Active, not recruiting

Conditions: Metastatic Breast Cancer

Interventions: Drug: Paclitaxel
Drug: AZD5363
Drug: Placebo

First Posted Date: 2015-04-22

Last Posted Date: 2024-06-20

Lead Sponsor: Queen Mary University of London

Target Recruit Count: 140

Registration Number: NCT02423603

Locations: 🇭🇺
University of Pécs - Clinical Center Institute of Oncotherapy, Pécs, Hungary
🇷🇴
Center of Oncology Euroclinic, Iași, Romania
🇫🇷
ICO René Gauducheau, Nantes, France

and more 43 locations

UK Trial of Percutaneous Tibial Nerve Stimulation in Patients With Faecal Incontinence

Phase 3

Completed

Conditions: Bowel Incontinence
Faecal Incontinence

Interventions: Device: Percutaneous Tibial Nerve Stimulation

First Posted Date: 2015-01-28

Last Posted Date: 2015-01-28

Lead Sponsor: Queen Mary University of London

Target Recruit Count: 227

Registration Number: NCT02349334

ESTEEM - Effect of Simple, Targeted Diet in Pregnant Women With Metabolic Risk Factors on Pregnancy Outcomes

Not Applicable

Completed

Conditions: Obesity
Pre-eclampsia
Small for Gestational Age
Stillbirth
Gestational Diabetes
Raised Lipids
High Blood Pressure
Insulin Resistance

Interventions: Other: Non-randomised cohort
Behavioral: Targeted ESTEEM diet

First Posted Date: 2014-08-18

Last Posted Date: 2017-11-17

Lead Sponsor: Queen Mary University of London

Target Recruit Count: 3442

Registration Number: NCT02218931

Locations: 🇬🇧
Barts Health NHS Trust, London, United Kingdom

A Randomized Study of AZD2014 in Combination With Fulvestrant in Metastatic or Advanced Breast Cancer

Phase 2

Completed

Conditions: Estrogen Receptor Positive Breast Cancer

Interventions: Drug: Everolimus
Drug: AZD2014
Drug: Fulvestrant

First Posted Date: 2014-08-15

Last Posted Date: 2024-12-02

Lead Sponsor: Queen Mary University of London

Target Recruit Count: 333

Registration Number: NCT02216786

Locations: 🇬🇪
Tbilisi Cancer Center, Tbilisi, Georgia
🇵🇹
Ipo Porto, Porto, Portugal
🇭🇺
Bacs-Kiskun County Hospital, Kalocsa, Hungary

and more 76 locations

Study to Measure the Effect of Part Time Versus Full Time Orthodontic Appliance Wear

Not Applicable

Conditions: Class II Division 1 Malocclusion

Interventions: Device: Modified Clark Twin Block

First Posted Date: 2014-07-15

Last Posted Date: 2017-01-04

Lead Sponsor: Queen Mary University of London

Target Recruit Count: 62

Registration Number: NCT02190630

Locations: 🇬🇧
Dental Insitiute Royal London Hospital, London, United Kingdom

Anterior Resection Syndrome Following Sphincter-preserving Surgery

Completed

Conditions: Rectal Cancer

First Posted Date: 2014-07-15

Last Posted Date: 2016-04-05

Lead Sponsor: Queen Mary University of London

Target Recruit Count: 1197

Registration Number: NCT02190656

Locations: 🇬🇧
Queen Mary University of London, London, United Kingdom

Characterising Metastatic Penile Cancer Using Molecular Imaging - Hybrid MRI-PET [MRI-PET]

Completed

Conditions: Squamous Cell Carcinoma of the Penis

Interventions: Procedure: MRI-PET

First Posted Date: 2014-04-04

Last Posted Date: 2024-07-08

Lead Sponsor: Queen Mary University of London

Target Recruit Count: 107

Registration Number: NCT02104063

Locations: 🇬🇧
University College London Hospitals, London, United Kingdom

Protective Role of Oxcarbazepine in Multiple Sclerosis

Phase 2

Completed

Conditions: Multiple Sclerosis

Interventions: Drug: Placebo
Drug: Oxcarbazepine

First Posted Date: 2014-04-04

Last Posted Date: 2018-04-18

Lead Sponsor: Queen Mary University of London

Target Recruit Count: 30

Registration Number: NCT02104661

Locations: 🇬🇧
Barts Health NHS Trust, London, United Kingdom

Telaprevir in Genotype 3 HCV

Phase 4

Completed

Conditions: Hepatitis C

Interventions: Drug: Telaprevir
Drug: 40 Kd Pegylated interferon alfa 2a
Drug: Ribavirin

First Posted Date: 2014-03-14

Last Posted Date: 2023-01-05

Lead Sponsor: Queen Mary University of London

Target Recruit Count: 14

Registration Number: NCT02087111

Locations: 🇬🇧
Nottingham University Hospitals Trust, Nottingham, United Kingdom
🇬🇧
Bradford Teaching Hospitals NHS Foundation Trust, Bradford, United Kingdom
🇬🇧
Ste Georges Healthcare NHS Trust, London, United Kingdom

and more 1 locations

Treatment of Iron Deficiency Anaemia in Inflammatory Bowel Disease With Ferrous Sulphate

Phase 4

Completed

Conditions: Ulcerative Colitis
Crohn's Disease

Interventions: Drug: Ferrous sulphate

First Posted Date: 2013-11-25

Last Posted Date: 2017-05-09

Lead Sponsor: Queen Mary University of London

Target Recruit Count: 90

Registration Number: NCT01991314

Locations: 🇬🇧
Barts Health NHS Trust, London, United Kingdom

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy